Evaluation of biomarkers panels in participants with BOS over the first 3 months of ruxolitinib therapy. Median levels of 3 biomarkers to demonstrate a response effect (VEGF, REG3α, and CCL15) at baseline, after 1 month, and after 3 months of ruxolitinib in responders and nonresponders, with response defined according to NIH criteria.